Zobrazeno 1 - 10 of 38 pro vyhledávání: '"E. M. Terveer"'
1
Akademický článek
Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial
Autor: J. S. W. Borgers, F. H. Burgers, E. M. Terveer, M. E. van Leerdam, C. M. Korse, R. Kessels, C. C. Flohil, C. U. Blank, T. N. Schumacher, M. van Dijk, J. G. E. Henderickx, J. J. Keller, H. W. Verspaget, E. J. Kuijper, J. B. A. G. Haanen
Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background The gut microbiome plays an important role in immune modulation. Specifically, presence or absence of certain gut bacterial taxa has been associated with better antitumor immune responses. Furthermore, in trials using fecal microb
Externí odkaz: https://doaj.org/article/6bd20975d8584eeab94f604ed9b0c810
Zobrazit plný text záznamu
2
Akademický článek
Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent infection in patients with inflammatory bowel disease
Autor: Emilie (E.) van Lingen, Simon (S. M. D.) Baunwall, Simone (S. C.) Lieberknecht, Nicolas (N.) Benech, Gianluca (G.) Ianiro, Harry (H.) Sokol, Alessandro (A.) Gasbarrini, Giovanni (G.) Cammarota, Marcel (M. K.) Eriksen, Andrea (A. E.) van der Meulen-de Jong, Elizabeth (E. M.) Terveer, Hein (H. W.) Verspaget, Maria (M.) Vehreschild, Christian (C. L.) Hvas, Josbert (J. J.) Keller
Publikováno v: Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Patients with inflammatory bowel disease (IBD) are at an increased risk of developing Clostridioides difficile infection (CDI). Treatment of CDI in patients with IBD is challenging due to higher failure rates and concomitant IBD activity.
Externí odkaz: https://doaj.org/article/d1e5885c4fe14d608dda3e4027daaf28
Zobrazit plný text záznamu
3
Akademický článek
Ten-Year Follow-Up of Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection from a Randomized Controlled Trial and Review of the Literature
Autor: R. E. Ooijevaar, E. van Nood, A. Goorhuis, E. M. Terveer, J. van Prehn, H. W. Verspaget, Y. H. van Beurden, M. G. W. Dijkgraaf, J. J. Keller
Publikováno v: Microorganisms, Vol 9, Iss 3, p 548 (2021)
Fecal microbiota transplantation (FMT) has become a well-established treatment for recurrent Clostridioides difficile infection (rCDI). While short-term outcomes and adverse events relating to FMT have been well documented, there still is a paucity o
Externí odkaz: https://doaj.org/article/4f6c99738201456da614143db6c60e92
Zobrazit plný text záznamu
4
Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease
Autor: Emilie (E.) van Lingen, Simon (S. M. D.) Baunwall, Simone (S. C.) Lieberknecht, Nicolas (N.) Benech, Gianluca (G.) Ianiro, Harry (H.) Sokol, Alessandro (A.) Gasbarrini, Giovanni (G.) Cammarota, Marcel (M. K.) Eriksen, Andrea (A. E.) van der Meulen-de Jong, Elizabeth (E. M.) Terveer, Hein (H. W.) Verspaget, Maria (M.) Vehreschild, Christian (C. L.) Hvas, Josbert (J. J.) Keller
Publikováno v: van Lingen, E, Baunwall, S, Lieberknecht, S, Benech, N, Ianiro, G, Sokol, H, Gasbarrini, A, Cammarota, G, Eriksen, M, van der Meulen-de Jong, A, Terveer, E, Verspaget, H, Vehreschild, M, Hvas, C & Keller, J 2023, ' Short-and long-term follow-up after fecal microbiota transplantation as treatment for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease ', Therapeutic Advances in Gastroenterology, vol. 16 . https://doi.org/10.1177/17562848231156285
Background: Patients with inflammatory bowel disease (IBD) are at an increased risk of developing Clostridioides difficile infection (CDI). Treatment of CDI in patients with IBD is challenging due to higher failure rates and concomitant IBD activity.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ae34fbbe36826e125dd2de3ffee8d38
https://doi.org/10.1177/17562848231156285
Zobrazit plný text záznamu
5
P328 Faecal microbiota transplantation as treatment for recurrent Clostridiodes difficile infection in patients with inflammatory bowel disease: Experiences of the Netherlands donor faeces bank
Autor: Ed J. Kuijper, E Van Lingen, E M Terveer, A. E. van der Meulen-de Jong, Josbert J. Keller, K E W Vendrik
Publikováno v: Journal of Crohn's and Colitis. 14:S317-S318
Background In recent years Faecal Microbiota Transplantation (FMT) is effectively implemented as an approved treatment approach of refractory Clostridiodes difficile infection (rCDI). In patients with inflammatory bowel disease (IBD) the prevalence o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2b98d3b4d8072669e82a13d25e874f25
https://doi.org/10.1093/ecco-jcc/jjz203.457
Zobrazit plný text záznamu
6
[Faecal microbiota transplantation: indications in perspective]
Autor: Y H, van Beurden, E M, Terveer, J J, Keller, E J, Kuijper, C J J, Mulder, C M J E, Vandenbroucke-Grauls
Publikováno v: Nederlands tijdschrift voor geneeskunde. 161
As yet, with cure rates around 85%, recurrent Clostridium difficile infection is the only definite indication for faecal microbiota transplantation.- Faecal microbiota transplantation induces clinical remission and endoscopic improvements in 24-30% o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b51747628fe51a19a402032e83e06068
https://pubmed.ncbi.nlm.nih.gov/29076444
Zobrazit plný text záznamu
7
The tortuous history of the implementation of early ambulation after delivery
Autor: Catharina Jacoba Maria Doggen, K.J. van Stralen, F.M. Helmerhorst, E M Terveer, Jan P. Vandenbroucke
Publikováno v: Journal of the Royal Society of Medicine, 100(2), 90-96. SAGE Publications
One of earliest known risk factors for venous thrombosis is pregnancy. As long ago as 1718 Mauriceau described the ‘milk leg’. He suspected that, in pregnant women, a venous thrombosis in the leg was caused by ‘redundancy and metastasis’ of b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106b8bb2ccb5fbc255dff5a692b862a7
https://doi.org/10.1258/jrsm.100.2.90
Zobrazit plný text záznamu
8
Akademický článek
Impact of Clinical and Pharmacological Parameters on Faecal Microbiota Transplantation Outcome in Clostridioides difficile Infections: Results of a 5-Year French National Survey.
Autor: Benech N; French Faecal Transplant Group (GFTF), France.; Hepato-Gastroenterology Department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.; Lyon GEM Microbiota Study Group, Lyon, France.; ESGHAMI (ESCMID Study Group for Host and Microbiota Interactions), Basel, Switzerland.; Claude Bernard Lyon 1 University, CRCL, Lyon, France.; ESGCD (ESCMID Study Group for Clostridioides difficile), Basel, Switzerland., Cassir N; French Faecal Transplant Group (GFTF), France.; Pôle Maladies Infectieuses et Tropicales. Assistance Publique-Hôpitaux de Marseille, Marseille, France.; Aix-Marseille Université, IRD, MEPHI, Marseille, France., Alric L; French Faecal Transplant Group (GFTF), France.; Internal Medecine-Digestive Department, Rangueil Hospital, Toulouse 3 University, France., Barbut F; French Faecal Transplant Group (GFTF), France.; ESGCD (ESCMID Study Group for Clostridioides difficile), Basel, Switzerland.; Institut National de la Santé et de la Recherche Médicale (INSERM) UMR S-1139, Université de Paris Cité, Paris, France.; National Reference Laboratory for Clostridioides Difficile, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, Paris, France., Batista R; French Faecal Transplant Group (GFTF), France.; Pharmacy Department, Cochin Hospital, APHP, Paris, France., Bleibtreu A; French Faecal Transplant Group (GFTF), France.; Department of Infectious Diseases, Pitié-Salpêtrière Hospital, APHP and Sorbonne Université, Paris, France.; INSERM U 1135, Cimi-Paris, Paris, France.; Assistance Publique-Hôpitaux de Paris (AP-HP) FMT Center, Paris, France., Briot T; French Faecal Transplant Group (GFTF), France.; Pharmacy Department, Hospices Civils de Lyon, Groupement Hospitalier Nord, Lyon, France., Davido B; French Faecal Transplant Group (GFTF), France.; Maladies Infectieuses, Hôpital Raymond Poincaré, Université Paris Saclay, Garches, France., Galperine T; French Faecal Transplant Group (GFTF), France.; Service Des Maladies Infectieuses, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Joly AC; French Faecal Transplant Group (GFTF), France.; Assistance Publique-Hôpitaux de Paris (AP-HP) FMT Center, Paris, France.; Saint-Antoine Hospital, Unité de Préparation Des Transplants de Microbiote (UPTM), Paris, France.; Paris Center for Microbiome Medicine (PaCeMM) FHU, Paris, France., Kapel N; French Faecal Transplant Group (GFTF), France.; Laboratoire de Coprologie, APHP, GH Pitié-Salpêtrière, Paris, France.; INSERM S1139, Faculté de Pharmacie, Université Paris Cité, Paris, France., Melchior C; French Faecal Transplant Group (GFTF), France.; Department of Gastroenterology, Univ Rouen Normandie, INSERM, Normandie Univ, ADEN UMR1073, Nutrition, Inflammation and Microbiota-Gut-Brain Axis, CHU Rouen, CIC-CRB 1404, Rouen, France., Mosca A; French Faecal Transplant Group (GFTF), France.; Service de Gastroentérologie et Nutrition Pédiatriques, Hôpital Robert-Debré, APHP, Paris, France., Nebbad B; French Faecal Transplant Group (GFTF), France.; Hôpital Henri Mondor, AP-HP, Unité de Transplantation de Microbiote Faecal, Créteil, France., Pigneur B; French Faecal Transplant Group (GFTF), France.; Service de Gastro-Entérologie et Nutrition Pédiatrique, Centre de Référence des Maladies Rares Digestives (MARDI), Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants Malades, Université Paris Cité, Paris, France.; INSERM UMR S 1139, Faculté de Pharmacie de Paris, Université Paris Cité, Paris, France., Schneider SM; French Faecal Transplant Group (GFTF), France.; Gastroentérologie et Nutrition, CHU Archet, Université Côte d'Azur, Nice, France., Wasiak M; French Faecal Transplant Group (GFTF), France.; Pôle Pharmacie, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France., Scanzi J; French Faecal Transplant Group (GFTF), France.; Centre Hospitalier de Thiers, Thiers, France.; University Hospital of Clermont Ferrand, Clermont Ferrand, France., Sokol H; French Faecal Transplant Group (GFTF), France.; Assistance Publique-Hôpitaux de Paris (AP-HP) FMT Center, Paris, France.; Paris Center for Microbiome Medicine (PaCeMM) FHU, Paris, France.; Gastroenterology Department, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint-Antoine Hospital, Sorbonne Université, Paris, France.; INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, France.
Publikováno v: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 Oct 10. Date of Electronic Publication: 2024 Oct 10.
Zobrazit plný text záznamu
9
Akademický článek
The Next Generation Fecal Microbiota Transplantation: To Transplant Bacteria or Virome.
Autor: Yu, You1,2 (AUTHOR), Wang, Weihong1,2 (AUTHOR), Zhang, Faming1,2,3 (AUTHOR) fzhang@njmu.edu.cn
Publikováno v: Advanced Science. Dec2023, Vol. 10 Issue 35, p1-17. 17p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje